Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Loses Neuroscience Chief To Johnson & Johnson

Executive Summary

Eli Lilly & Co. continues to search for a new head of neurology research as its diagnostic drug Amyvid (florbetapir F 18 injection) nears its user fee goal date.

You may also be interested in...



Amyvid Training Issues Lead To Complete Response Letter, Could Force More Trials

FDA says consistent training program needed for market implementation of amyloid diagnostic. Lilly says issues will be resolved promptly.

Amyvid Approval Delay Seems Likely; Questions On Utility Of Training, Plaque Detection Itself Remain

It appears the training program for Amyvid may still need some work, but Eli Lilly & Co. remains confident the diagnostic will gain FDA approval.

Can Amyvid Be An Important Alzheimer's Product Without An Alzheimer's Indication?

Members of the FDA advisory committee that reviewed Avid Radiopharmaceuticals' Amyvid appear less enthusiastic about the product's immediate prospects than the firm itself, but actually could be more enthusiastic about the diagnostic's long-term utility than even the sponsor.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053213

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel